Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Peripheral/Central Venous Blood Draw Clear all
Recruiting No phase listed Observational

A Clinical Registry to Demonstrate the Safety and Performance of Teleflex Vascular Access Devices

NCT06604039
View directory record Official record
Conditions
Vascular Access Device
Interventions
Central venous catheter
Device
Lead sponsor
Teleflex
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Timeline
2024 – 2034
U.S. locations
3
States / cities
Huntsville, Alabama • Loma Linda, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 1Phase 2 Interventional

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

NCT00572013
View directory record Official record
Conditions
Lymphoma
Interventions
Rituxan, BEAM, Autologous stem cell transplant
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

NCT01198327
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
ranibizumab, Peripheral Laser
Drug · Other
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 21, 2026, 9:24 AM EDT
Active, not recruiting Not applicable Interventional

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

NCT03537586
View directory record Official record
Conditions
Coronary Microvascular Disease, Ischemic Heart Disease, Myocardial Ischemia
Interventions
Bivalirudin, Adenosine, Heparin, Pressure-Temperature Sensor Guidewire, Guiding Catheter
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 125 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Busulfan and Fludarabine in Patients With AML and MDS

NCT00502905
View directory record Official record
Conditions
Leukemia
Interventions
Busulfan, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 66 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 21, 2026, 9:24 AM EDT
Terminated No phase listed Observational

A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture

NCT02402829
View directory record Official record
Conditions
Hemophilia A, Factor VIII Deficiency, Hemophilia, Hemophilia B, Factor IX Deficiency
Interventions
Peripheral Vein Blood draw
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 21 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

NCT00253435
View directory record Official record
Conditions
Neuroblastoma
Interventions
Filgrastim, Carboplatin, Etoposide, Melphalan, Peripheral blood stem cell infusion, 131I-MIBG, Radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 29 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 21, 2026, 9:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector

NCT05432310
View directory record Official record
Conditions
Adenosine Deaminase Severe Combined Immune Deficiency
Interventions
A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Month and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 21, 2026, 9:24 AM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 21, 2026, 9:24 AM EDT
Completed No phase listed Observational

Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction

NCT00588510
View directory record Official record
Conditions
Osteosarcoma
Interventions
Blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion

NCT01710839
View directory record Official record
Conditions
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Interventions
0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 21, 2026, 9:24 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

NCT03807973
View directory record Official record
Conditions
Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy
Interventions
[Zr-89]Oxine-labeled leukocytes PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters

NCT00728819
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Tapered PICC, Non-tapered PICC
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 1 Interventional

N99-02: Melphalan and Buthionine Sulfoximine

NCT00005835
View directory record Official record
Conditions
Neuroblastoma
Interventions
buthionine sulfoximine, melphalan, Peripheral blood stem cell infusion, Filgrastim
Drug · Procedure · Other
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
Up to 30 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 21, 2026, 9:24 AM EDT
Completed No phase listed Observational

Circulating Tumor Cells in Operative Blood

NCT02150746
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
Peripheral/Central Venous Blood Draw, Peritoneal Wash
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 21, 2026, 9:24 AM EDT
Not yet recruiting Phase 1 Interventional

Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders

NCT07585136
View directory record Official record
Conditions
Bone Marrow Failure Syndrome
Interventions
Filgrastim, Plerixafor, Leukapheresis
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 21, 2026, 9:24 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

NCT02653443
View directory record Official record
Conditions
Healthy
Interventions
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets., Autologous apheresis Conventional untreated Platelet Components
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Lebanon, New Hampshire • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 21, 2026, 9:24 AM EDT
Not yet recruiting Not applicable Interventional

Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis

NCT07755059
View directory record Official record
Conditions
Ascites, Liver Cirrhosis, Hypertension, Portal
Interventions
Proximal Splenic Artery Embolization
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 21, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

NCT00217425
View directory record Official record
Conditions
Lymphoma
Interventions
bevacizumab, cyclophosphamide, doxorubicin, prednisone, vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
110
States / cities
Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 21, 2026, 9:24 AM EDT
Terminated No phase listed Observational

Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status

NCT03407287
View directory record Official record
Conditions
Systemic Inflammatory Response Syndrome, Distributive Shock, Hypotension and Shock, Decompensated Congestive Heart Failure, Atrial Fibrillation, High Risk Non-cardiac Surgery
Interventions
Peripheral Intravenous Analysis (PIVA), Standard of care invasive vascular monitoring, Standard noninvasive vascular monitoring
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 21, 2026, 9:24 AM EDT